Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP)
(WorldNews Health)

November 11, 2019 Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) Mitsubishi Tanabe Pharma Corporation (MTPC) announces successful completion of the ENDEAVOR study for MT-7117 (dersimelagon - selective MC1R agonist), an investigational oral treatment under development by Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) for the prevention of phototoxicity (including severe pain on exposure to sunlight) in patients with erythropoietic protoporphyria (EPP).1 ENDEAVOR is a phase 2 proof of concept study for MT-7117 as a treatment option for EPP. ENDEAVOR met its primary endpoint of...